BioSpace News Archive

Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.

QurAlis’ first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time.

Active Biotech announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy at the 25th World Congress of Neurology taking place October 3-7, 2021.

Brii Biosciences Limited presented at IDWeek 2021 interim results from Phase 3 of the ACTIV-2 trial, which showed that BRII-196/BRII-198, the Company’s neutralizing monoclonal antibody combination therapy for SARS-CoV-2, achieved a similar reduction in hospitalization or death among patients who initiated treatment early versus late following symptom onset.